This article summarized the latest R&D progress of Menotropins, the Mechanism of Action for Menotropins, and the drug target R&D trends for Menotropins.

In biology, linkers refer to short amino acid sequences found in nature that separate multiple domains in a single protein.

Otsuka Pharmaceutical and Visterra recently reported that the full Phase II trial results for sibeprenlimab (VIS649), a treatment for IgA nephropathy, have been published in the NEJM.

This article summarized the latest R&D progress of Metadoxine, the Mechanism of Action for Metadoxine, and the drug target R&D trends for Metadoxine.

HuidaGene Therapeutics, a global oncology-focused biotech company, has announced its first treatment in its multinational HG004 gene therapy study (STAR study). This phase 1/2a investigation uses CRISPR-influenced programmable genomic drugs to potentially treat inherited retinal dystrophies caused by RPE65 gene mutations.

An intron, derived from the term "intragenic region", is a nucleotide sequence within a gene that does not directly code for proteins and does not remain in the final mature mRNA molecule following the gene's transcription.

This article summarized the latest R&D progress of Metyrosine, the Mechanism of Action for Metyrosine, and the drug target R&D trends for Metyrosine.

Novartis reported FDA's approval of Cosentyx® (secukinumab) for the management of moderate to extreme hidradenitis suppurativa in adult patients.

This article summarized the latest R&D progress of Mexazolam, the mechanism of action for Mexazolam, and the drug target R&D trends for Mexazolam.

The FDA has given its sanction for Wezlana (ustekinumab-auub), considering it a biosimilar and substitute for Stelara (ustekinumab) in treating several inflammatory conditions.

In a hairpin sequence, the strand loops out and then come back to pair with itself, forming a double helix (the stem) ending in an unpaired loop.

The U.S. Food and Drug Administration (FDA) has given permission to resume the Phase 1 clinical trial of XMT-2056, according to Mersana Therapeutics, Inc., a biopharmaceutical firm in the clinical stage.